Drug intelligence / Profile preview

ivermectin + metronidazole

Development stage
Phase 3
Lead developer
Merck
Modality
Small Molecules
Administration
Topical
01

Overview

Ivermectin + metronidazole is a topical combination medication that works through dual mechanisms to treat inflammatory skin conditions, particularly rosacea and Demodex-related disorders. Ivermectin functions as both an anti-inflammatory agent and an antiparasitic that targets Demodex mites, which have been implicated in rosacea pathophysiology. Metronidazole reduces reactive oxygen species, decreases oxidative tissue injury by inhibiting neutrophil-generated cytokines, and provides additional anti-inflammatory and antimicrobial effects. Clinical studies have shown this combination to be more effective than either agent alone, with superior efficacy in reducing inflammatory lesions, eradicating Demodex mites, and improving overall skin condition. The combination has demonstrated complete Demodex eradication, improved tear film parameters in patients with meibomian gland dysfunction, and reduced ocular symptoms.

Other names
Ivermectin/metronidazole topicalIvermectin-metronidazole gel
02

Targets

DNAGluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on ivermectin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivermectin + metronidazole.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call